Co-Developed OCT Spectroscopy Device Moving to Clinical Testing

Kent Imaging announced today that an OCT spectroscopy device, co-developed with the National Research Council of Canada (NRC), is moving to clinical testing. The completed new technology is being transported to a Toronto hospital to begin the first stage of clinical testing.

Previous
Previous

Kent Imaging Appoints Healthcare Veteran as CEO